Concerns Rise Over Jay Bhattacharya's Dual Role at NIH and CDC

Jay Bhattacharya, currently serving as the acting director of the U.S. Centers for Disease Control and Prevention (CDC) while maintaining his position as the permanent director of the National Institutes of Health (NIH), faces growing concerns from NIH employees regarding his ability to effectively manage both roles. Bhattacharya's leadership has been marked by significant changes at NIH, including a reduction in funding for research, particularly studies related to race and gender, and a troubling rise in health insurance costs for early-career scientists.

The Guardian

The NIH, which oversees a budget of $48.7 billion, is experiencing a leadership vacuum, with over half of its 27 institutes and centers currently led by acting directors. This situation raises alarms about the future of scientific research in the U.S., as the success rate for early-career scientists applying for R01 grants has plummeted from 26.1% in fiscal year 2024 to 18.9% in fiscal year 2025. Shiv Prasad, a scientific review officer at NIH, emphasized that the lack of permanent leadership is detrimental to the agency's mission and the overall scientific pipeline.

The Guardian

Critics have voiced concerns about Bhattacharya's commitment to his responsibilities at NIH, suggesting that he spends considerable time on right-wing media engagements rather than focusing on the agency's pressing issues. Prasad noted that the current situation is unprecedented, as no previous NIH director has treated the role as part-time. Employees worry that Bhattacharya's divided attention could hinder the agency's effectiveness in addressing critical scientific and administrative challenges.

The Guardian

Emily G. Hilliard, press secretary for the Department of Health and Human Services (HHS), stated that the CDC leadership team is collaborating closely with Bhattacharya during this interim period to ensure continuity in protecting public health. However, Prasad and other NIH employees argue that both the NIH and CDC require dedicated leadership to address their unique challenges effectively.

The Guardian

There is a notable discrepancy regarding the effectiveness of Bhattacharya's dual role. While some employees, like Matthew Memoli, the principal deputy director of NIH, are seen as effectively managing the agency, others express skepticism about the long-term implications of having a part-time director. Concerns about governance and accountability are heightened by the lack of clarity on decision-making responsibilities within the agency.

The Guardian

• “The NIH director position has always been a full-time job for everyone who’s held that position, and no one has treated it as a part-time job before,” — Shiv Prasad, Scientific Review Officer at NIH

The Guardian

• “If he’s already too busy to be able to address the real issues that scientists are facing at the NIH, then how is he now going to have the time to run things with this extra role?” — Ian Morgan, Postdoctoral Researcher at NIH

The Guardian

• “Even at a second job, we should worry about the harms to governance. It is hard to do two full-time jobs.” — Anne Joseph O’Connell, Professor at Stanford Law School

The Guardian

As Jay Bhattacharya navigates his dual responsibilities at the NIH and CDC, the implications for both agencies remain uncertain. The concerns raised by NIH employees highlight the potential risks of divided leadership in critical public health and research institutions, emphasizing the need for dedicated attention to their respective missions.

The Guardian